Search

Your search keyword '"maryam afshani"' showing total 3 results
Start Over Author "maryam afshani" Publication Year Range Last 3 years
3 results on '"maryam afshani"'

1. The effect of sprint interval training with short repetitions on hippocampal Brain-derived neurotrophic factor levels, learning and spatial memory in adult Wistar rats

Author

Maryam Afshani, Esmail Nasiri, and Mohsen Khalili

Subjects
sprint interval training, brain-derived neurotrophic factor, learning and memory, rats, Medicine
Abstract

Background: Different intensities of exercise may have a different effect on the level of brain-derived neurogenic factor (BDNF). Hence, this study aimed to determine the effect of sprint interval training with short repetitions on hippocampal BDNF level, spatial learning and memory in adult rats. Materials and Methods: Sixteen Wistar rats were randomly divided into the control (CO, n=8) and exercise (EX, n=8) groups. The exercise was performed for 8 weeks, 3 sessions per week, 4-9 repetitions of 10 seconds sprints, and 1-minute rest. At the end of the training period, the learning and memory of the animals were evaluated by Y maze and shuttle box tests. 48 hours after the test, the rats were anesthetized and the hippocampal tissue was isolated. BDNF levels were measured in hippocampal tissue homogeneity. The independent t-test was used to analyze the data at the alpha level of 0.05. Results: Statistical analysis of the data showed that the level of BDNF in EX hippocampus was significantly higher than that of CO (P

Published
2023

2. Evaluation of the safety and efficacy of a biosimilar abobotulinum toxin type A in treating moderate‐to‐severe glabellar lines: A non‐inferiority double blinded randomized controlled trial

Author

Seyyedeh Maryam Afshani, Aniseh Samadi, Azin Ayatollahi, Mansour Nassiri Kashani, Saman Ahmad Nasdrollahi, Hamed Hosseini, Zahra Rezagholi, Behnaz Hedayatjoo, Delara Hazegh Fetratjoo, Mohammad Amin Ghobadi, AmirHossein Anari, Sajjad Saeedifar, and Alireza Firooz

Subjects
Treatment Outcome, Double-Blind Method, Neuromuscular Agents, Humans, Forehead, Dermatology, Botulinum Toxins, Type A, Biosimilar Pharmaceuticals, Skin Aging
Abstract

Injection of botulinum toxin for cosmetic purposes is a well-established practice.This study was conducted to compare the safety and efficacy of DystonOut of 193 screened subjects, 126 volunteers with moderate-to-severe glabellar lines fulfilling eligibility criteria were randomized in a 1:1 ratio to receive either an intramuscular injection of 40-60 units of DystonResponse rates at maximum frown were 75.44% (43/57) in the DystonTreatment of moderate-to-severe glabellar lines with Dyston

Published
2022
Full Text
View/download PDF

3. Immunogenicity and safety of a bivalent, adjuvant system 04–adjuvanted human papillomavirus vaccine in healthy female volunteers aged 15–25: a randomized, double-blind, phase III, noninferiority clinical trial

Author

Seyyedeh Maryam, Afshani, Reihaneh, Mirhassani, Hamed, Hosseini, Reihaneh, Hosseini, Afsaneh, Tehranian, Reza, Malekzadeh, Afshin, Ostovar, Amir Hossein, Abdolghaffari, Mohammad Amin, Ghobadi, Behnaz, Hedayatjoo, Delara, Hazegh Fetratjoo, Zahra, Rezagholi, AmirHossein, Anari, and Ashraf, Moini

Subjects
Cancer Research, Epidemiology, Papillomavirus Infections, Public Health, Environmental and Occupational Health, Aluminum Hydroxide, Iran, Antibodies, Viral, Healthy Volunteers, Lipid A, Oncology, Humans, Female, Papillomavirus Vaccines, Papillomaviridae
Abstract

Vaccination is proven to significantly reduce the risk of human papillomavirus (HPV)-related complications, especially cervical cancer. This study aimed to assess the immunogenicity and safety of the investigational bivalent HPV vaccine (16/18), named Papilloguard (Noyan Pajouhan Biopharma, Tehran, Iran), in comparison with the reference product (Cervarix, bivalent HPV vaccine (16/18) manufactured by GlaxoSmithKline, Rixensart, Belgium) in a three-dose regimen.This trial was a randomized, controlled, double-blind, phase III study of two HPV vaccines in healthy female volunteers aged 15-25. The primary endpoint was to test the noninferiority of Papilloguard (Noyan Pajouhan Biopharma) to Cervarix (GlaxoSmithKline) as measured by the geometric mean titer (GMT) ratios of HPV-16 and HPV-18 7 months after the first vaccination. Secondary endpoints were the proportion of local and systemic solicited and unsolicited events, and the number of females with seroconversion against HPV-16 and HPV-18 7 months after the first vaccination.Out of 504 screened women, 218 were enrolled. Seven months after the first vaccination, GMT ratios of HPV-16 and HPV-18 were 0.59 and 0.93, respectively. The seroconversion rates of both Papilloguard (Noyan Pajouhan Biopharma) and Cervarix (GlaxoSmithKline) were more than 96%. Both vaccinated groups had a generally good profile of solicited and unsolicited adverse events (AEs). The most common AE was discomfort at the injection site, which was well tolerated.The result analysis of this study supports the noninferiority of Papilloguard (Noyan Pajouhan Biopharma) to Cervarix (GlaxoSmithKline) in terms of safety and immunogenicity based on the GMT ratio. However, long-term comparative studies to evaluate the sustainability of GMT response and risk of cervical intraepithelial neoplasia grades 2-3 are needed.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results